Outlook on the Peptide and Oligonucleotide CDMO Market: Major Segments, Strategic Developments, and Leading Companies

The peptide and oligonucleotide CDMO market is poised for significant expansion over the coming years, driven by advances in therapeutics and manufacturing technologies. This industry plays a critical role in supporting drug development pipelines, especially for rare diseases and oncology, by providing specialized contract development and manufacturing services. Let's explore the current market size, leading companies, emerging trends, and detailed segment insights shaping this space.

Forecasted Market Size and Growth Trajectory of the Peptide and Oligonucleotide CDMO Market
The peptide and oligonucleotide CDMO market is projected to experience rapid growth, reaching a valuation of $4.03 billion by 2030. This corresponds to a compound annual growth rate (CAGR) of 10.5% during the forecast period. The expansion is fueled by several key factors including the broadening pipeline of oligonucleotide therapeutics, increasing investments in rare disease and oncology drug development, and a rising need for swift production of clinical trial materials. Additionally, the market benefits from a growing preference for specialized CDMO partnerships and ongoing advancements in solid-phase synthesis technologies. Key trends driving this growth include the increasing outsourcing of peptide and oligonucleotide manufacturing, rising demand for cGMP-compliant production of complex molecules, the growth of end-to-end development and manufacturing services, heightened focus on high-potency and high-purity therapeutics, and wider adoption of scalable, flexible manufacturing platforms.

Download a free sample of the peptide and oligonucleotide cdmo market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Primary Companies Leading the Peptide and Oligonucleotide CDMO Market
Several major players dominate the peptide and oligonucleotide CDMO sector, including Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group AG, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, EUROAPI SA., CordenPharma International, Bachem Holding AG, GenScript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, and Sylentis S.A.

A notable recent development occurred in May 2024, when EUROAPI, a France-based CDMO, acquired BianoGMP, a German CDMO specializing in oligonucleotide analytical services, for an undisclosed sum. This acquisition strengthens EUROAPI's position in oligonucleotide contract development and manufacturing, complementing its existing capabilities in Frankfurt.

View the full peptide and oligonucleotide cdmo market report:
https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Trends Shaping the Future of the Peptide and Oligonucleotide CDMO Market
Leading organizations in the peptide and oligonucleotide CDMO market are increasingly forming strategic collaborations to enhance their technological expertise, expand services, and broaden their market presence. One example is the partnership announced in May 2023 between PolyPeptide Group AG, a US-based CDMO, and Numaferm GmbH, a German biotechnology firm. This alliance leverages PolyPeptide's cGMP manufacturing capabilities and market reach alongside Numaferm's expertise in sustainable peptide production and biochemical platforms. Their joint efforts focus on developing suitable peptide candidates aimed at more environmentally sustainable manufacturing of peptide-based active pharmaceutical ingredients (APIs).

Detailed Segment Analysis of the Peptide and Oligonucleotide CDMO Market
This market is segmented into the following major categories:
1) By Product: Peptides and Oligonucleotides
2) By Service Type: Contract Development and Contract Manufacturing
3) By Application: Therapeutics, Research Applications, Diagnostics, and Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, and Other End Users

Further subdivisions include:
- For Peptides: Active Pharmaceutical Ingredients (APIs), Peptide Drug Products, Peptide Synthesis and Manufacturing Services
- For Oligonucleotides: Antisense Oligonucleotides, siRNA and mRNA Oligonucleotides, Oligonucleotide Synthesis and Manufacturing Services

Together, these segments provide a comprehensive overview of the market dynamics and specialization areas within the peptide and oligonucleotide CDMO industry.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.